Depressive Symptoms, Antidepressant Medication Use, and Inflammatory Markers in the Diabetes Prevention Program
Antidepressant medication use (ADM) has been shown to predict diabetes. This paper assessed the role of inflammatory markers in this relationship within the Diabetes Prevention Program (DPP).Methods
DPP participants randomized to Metformin (MET), Lifestyle Intervention (ILS) or placebo (PLB) were assessed for depression (BDI; Beck Depression Inventory) annually; ADM use semi-annually; serum inflammatory markers (CRP, IL-6) at baseline and Year 1; and diagnosis of T2DM semi-annually (over 3.2 years).Results
At baseline (N=3,187), mean BMI was 34 kg/m2 (S.D. 6) and the median BDI score was 3 [interquartile range: 1-7]. 181 (5.7%) reported ADM use and 328 (10%) had BDI scores of >11. CRP and IL-6 levels did not differ by treatment group.Conclusions
ADM was significantly associated with elevated CRP and incident T2DM. In the PLB group, ADM and CRP independently predicted onset of T2DM, however CRP did not significantly mediate the effect of ADM.